0001193125-21-280095.txt : 20210923 0001193125-21-280095.hdr.sgml : 20210923 20210923075402 ACCESSION NUMBER: 0001193125-21-280095 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210923 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210923 DATE AS OF CHANGE: 20210923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Catalent, Inc. CENTRAL INDEX KEY: 0001596783 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208737688 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36587 FILM NUMBER: 211271061 BUSINESS ADDRESS: STREET 1: 14 SCHOOLHOUSE ROAD CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: (732) 537-6200 MAIL ADDRESS: STREET 1: 14 SCHOOLHOUSE ROAD CITY: SOMERSET STATE: NJ ZIP: 08873 FORMER COMPANY: FORMER CONFORMED NAME: PTS Holdings Corp. DATE OF NAME CHANGE: 20140113 8-K 1 d179941d8k.htm 8-K 8-K
false 0001596783 0001596783 2021-09-23 2021-09-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 23, 2021

 

 

CATALENT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36587   20-8737688

(State or other jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

14 Schoolhouse Road

Somerset, New Jersey

   08873
(Address of principal executive office)   (Zip code)

(732) 537-6200

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   CTLT   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Items.

Notes Offering

On September 23, 2021, Catalent, Inc. (the “Company”) issued a press release announcing that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Company”), has commenced a private offering (the “Private Offering”) of $450 million aggregate principal amount of senior unsecured notes due 2030 (the “Notes”). The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Operating Company is also in the process of amending its credit agreement (the “Amendment”) governing its senior secured credit facilities to, among other things, incur additional incremental term loans (the “Incremental Term Loans”) under its term loan facility (the “Dollar Term B-3 Facility”) in an aggregate amount of up to $450 million. The Operating Company expects that the Incremental Term Loans will be on the same terms as, and will be fungible and treated as a single class of term loans with, the existing term loans under its Dollar Term B-3 Facility.

The Operating Company intends to use the proceeds from the Private Offering, together with the Incremental Term Loan proceeds and cash on hand, to fund the purchase price for its previously announced acquisition of Bettera Holdings, LLC (the “Bettera Acquisition”) and to pay related fees, costs, and expenses. The Bettera Acquisition is not conditioned on the consummation of the Private Offering or the Amendment, and neither the Private Offering nor the Amendment is contingent on the consummation of the Bettera Acquisition.

There can be no assurance that the Operating Company will be able to complete either the Private Offering or the Amendment on terms and conditions favorable to it or at all, and the Operating Company may decide to not pursue either or both before completion.

The information furnished in this Form 8-K pursuant to Item 8.01, including the information contained in Exhibit 99.1, is neither an offer to sell nor a solicitation of an offer to buy any of the Notes in the Private Offering.

Cautionary Note Concerning Forward-Looking Statements

This Current Report on Form 8-K and the exhibit attached hereto contain both historical and forward-looking statements, including statements regarding the Bettera Acquisition, the Amendment, the Private Offering, and plans, projections and estimates regarding the use of proceeds from the Amendment and the Private Offering. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements generally can be identified because they relate to the topics set forth above or by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe the Company’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic on the Company’s or its clients’ or suppliers’ businesses, participation in a highly competitive market and increased competition may adversely affect the Company’s business; demand for the Company’s offerings which depends in part on its customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect the Company’s results of operations, financial condition, liquidity, and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on the business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political, and regulatory risks to the Company’s operations; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks, and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products the Company manufactures, including active pharmaceutical ingredients, excipients, purchased components, and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies; adverse

tax legislative or regulatory initiatives or challenges or adjustments to the Company’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisition, including the Bettera Acquisition, or other transaction that may complement or expand the business of the Company or divestment of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at the Company’s existing facilities; offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund the Company’s existing pension plans; substantial leverage resulting in the limited ability of the Company to raise additional capital to fund operations and react to changes in the economy or in the industry; exposure to interest rate risk to the extent of the Company’s variable rate debt and preventing the Company from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed August 30, 2021. All forward-looking statements speak only as of the date of this Current Report on Form 8-K or as of the date they are made, and the Company does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		    Description
99.1    Press Release of Catalent, Inc., dated September 23, 2021, announcing the launch of the Private Offering.
104    Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Catalent, Inc.
  (Registrant)
By:  

/s/ Steven L. Fasman

  Steven L. Fasman
 

Senior Vice President, General Counsel

and Secretary

Date: September 23, 2021

EX-99.1 2 d179941dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030

SOMERSET, N.J., September 23, 2021 — Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $450 million in aggregate principal amount of senior unsecured notes due 2030 (the “Notes”) in a private offering (the “Private Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).

The Operating Subsidiary intends to use the proceeds from the Private Offering to finance a portion of the purchase price for the previously announced acquisition of Bettera Holdings, LLC (the “Bettera Acquisition”) and to pay related fees, costs, and expenses (though neither the Private Offering nor the Bettera Acquisition is conditioned on the consummation of the other).

The Notes will be guaranteed by all of the wholly owned U.S. subsidiaries of the Operating Subsidiary that guarantee its senior secured credit facilities. The Notes will not be guaranteed by PTS Intermediate Holdings, LLC or Catalent, the direct and indirect parent companies of the Operating Subsidiary.

The Notes will be offered and sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to certain non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act.

The Notes have not been and will not be registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Notes or any other securities described above and shall not constitute an offer, solicitation or sale in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful.

There can be no assurance that the Operating Subsidiary will consummate either (i) the Private Offering on favorable terms or at all or (ii) the Bettera Acquisition.

About Catalent

Catalent, Inc. (NYSE: CTLT), an S&P 500® Company, is the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products. With almost 90 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable global clinical and commercial product supply. Catalent’s workforce exceeds 17,000 people, including more than 2,500 scientists and technicians, at more than 50 facilities on four continents, and in fiscal year 2021, it generated $4 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

Forward-Looking Statement Notice

This release contains both historical and forward-looking statements, including statements regarding the Bettera Acquisition, the Private Offering and plans, projections and estimates regarding the use of proceeds from the Private Offering. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified because they relate to the topics set forth above or by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe Catalent’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove

inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic on Catalent’s or its clients’ or suppliers’ businesses, participation in a highly competitive market and increased competition may adversely affect Catalent’s business; demand for Catalent’s offerings which depends in part on Catalent’s customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalent’s results of operations, financial condition, liquidity, and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on Catalent’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political, and regulatory risks to the operations of Catalent; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks, and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased components, and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies; adverse tax legislative or regulatory initiatives or challenges or adjustments to Catalent’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisition, including the Bettera Acquisition, or other transaction that may complement or expand Catalent’s business or divest of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at Catalent’s existing facilities; offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund Catalent’s existing pension plans; substantial leverage resulting in the limited ability of Catalent to raise additional capital to fund operations and react to changes in the economy or in the industry; exposure to interest rate risk to the extent of Catalent’s variable rate debt and preventing Catalent from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in Catalent’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed August 30, 2021. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.

Contact:

Catalent, Inc.

Investor Contact:

Paul Surdez, 732-537-6325

investors@catalent.com

EX-101.SCH 3 ctlt-20210923.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ctlt-20210923_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 ctlt-20210923_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 d179941d8k_htm.xml IDEA: XBRL DOCUMENT 0001596783 2021-09-23 2021-09-23 false 0001596783 8-K 2021-09-23 CATALENT, INC. DE 001-36587 20-8737688 14 Schoolhouse Road Somerset NJ 08873 (732) 537-6200 false false false false Common Stock, $0.01 par value per share CTLT NYSE false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Sep. 23, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001596783
Document Type 8-K
Document Period End Date Sep. 23, 2021
Entity Registrant Name CATALENT, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-36587
Entity Tax Identification Number 20-8737688
Entity Address, Address Line One 14 Schoolhouse Road
Entity Address, City or Town Somerset
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08873
City Area Code (732)
Local Phone Number 537-6200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol CTLT
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d179941d8k.htm ctlt-20210923.xsd ctlt-20210923_lab.xml ctlt-20210923_pre.xml d179941dex991.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d179941d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d179941d8k.htm" ] }, "labelLink": { "local": [ "ctlt-20210923_lab.xml" ] }, "presentationLink": { "local": [ "ctlt-20210923_pre.xml" ] }, "schema": { "local": [ "ctlt-20210923.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ctlt", "nsuri": "http://catalent.com/20210923", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d179941d8k.htm", "contextRef": "duration_2021-09-23_to_2021-09-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d179941d8k.htm", "contextRef": "duration_2021-09-23_to_2021-09-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://catalent.com//20210923/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-21-280095-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-280095-xbrl.zip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end